دورية أكاديمية
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
| العنوان: | A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. |
|---|---|
| المؤلفون: | Hahn NM; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA. Electronic address: nhahn4@jhmi.edu., O'Donnell MA; University of Iowa Carver College of Medicine, Iowa City, IA, USA., Efstathiou JA; Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Zahurak M; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Rosner GL; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Smith J; Hoosier Cancer Research Network, Indianapolis, IN, USA., Kates MR; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Bivalacqua TJ; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Division of Urology and Urologic Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Tran PT; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA., Song DY; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Baras AS; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Matoso A; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Choi W; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Smith KN; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Johns Hopkins Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA., Pardoll DM; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Johns Hopkins Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA., Marchionni L; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; Johns Hopkins University School of Medicine, Center for Computational Genomics, Baltimore, MD, USA; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., McGuire B; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Grace Phelan M; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Johnson BA 3rd; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., O'Neal T; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., McConkey DJ; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA; The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Division of Medical Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA., Bjurlin M; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Urology, University of North Carolina, Chapel Hill, NC, USA., Lim EA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Spectrum Health Medical Group, Grand Rapids, MI, USA., Drake CG; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Janssen Research and Development, Springhouse, PA, USA., McKiernan JM; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Urology, Columbia University, New York, NY, USA., Deutsch I; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Radiation Oncology, Columbia University, New York, NY, USA., Anderson CB; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; Department of Urology, Columbia University, New York, NY, USA., Lamm DL; BCG Oncology, Phoenix, AZ, USA., Geynisman DM; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Plimack ER; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Hallman MA; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Horwitz EM; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Al-Saleem E; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA., Chen DYT; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA., Greenberg RE; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA., Kutikov A; Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA., Guo G; Department of Radiation Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, USA; University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Masterson TA; Department of Urology, Indiana University Simon Cancer Center, Indianapolis, IN, USA., Adra N; Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, USA., Kaimakliotis HZ; Department of Urology, Indiana University Simon Cancer Center, Indianapolis, IN, USA. |
| المصدر: | European urology [Eur Urol] 2023 Jun; Vol. 83 (6), pp. 486-494. Date of Electronic Publication: 2023 Jan 28. |
| نوع المنشور: | Clinical Trial, Phase I; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : Amsterdam : Elsevier Science Original Publication: Basel, New York, Karger. |
| مواضيع طبية MeSH: | Non-Muscle Invasive Bladder Neoplasms* , Urinary Bladder Neoplasms*/pathology, Humans ; Urinary Bladder/pathology ; BCG Vaccine/adverse effects ; Administration, Intravesical ; Adjuvants, Immunologic ; Neoplasm Invasiveness/pathology ; Neoplasm Recurrence, Local/pathology |
| مستخلص: | Background: Novel treatments and trial designs remain a high priority for bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) patients. Objective: To evaluate the safety and preliminary efficacy of anti-PD-L1 directed therapy with durvalumab (D), durvalumab plus BCG (D + BCG), and durvalumab plus external beam radiation therapy (D + EBRT). Design, Setting, and Participants: A multicenter phase 1 trial was conducted at community and academic sites. Intervention: Patients received 1120 mg of D intravenously every 3 wk for eight cycles. D + BCG patients also received full-dose intravesical BCG weekly for 6 wk with BCG maintenance recommended. D + EBRT patients received concurrent EBRT (6 Gy × 3 in cycle 1 only). Outcome Measurements and Statistical Analysis: Post-treatment cystoscopy and urine cytology were performed at 3 and 6 -mo, with bladder biopsies required at the 6-mo evaluation. The recommended phase 2 dose (RP2D) for each regimen was the primary endpoint. Secondary endpoints included toxicity profiles and complete response (CR) rates. Results and Limitations: Twenty-eight patients were treated in the D (n = 3), D + BCG (n = 13), and D + EBRT (n = 12) cohorts. Full-dose D, full-dose BCG, and 6 Gy fractions × 3 were determined as the RP2Ds. One patient (4%) experienced a grade 3 dose limiting toxicity event of autoimmune hepatitis. The 3-mo CR occurred in 64% of all patients and in 33%, 85%, and 50% within the D, D + BCG, and D + EBRT cohorts, respectively. Twelve-month CRs were achieved in 46% of all patients and in 73% of D + BCG and 33% of D + EBRT patients. Conclusions: D combined with intravesical BCG or EBRT proved feasible and safe in BCG-unresponsive NMIBC patients. Encouraging preliminary efficacy justifies further study of combination therapy approaches. Patient Summary: Durvalumab combination therapy can be safely administered to non-muscle-invasive bladder cancer patients with the goal of increasing durable response rates. (Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.) |
| التعليقات: | Comment in: Eur Urol. 2023 Jun;83(6):495-496. (PMID: 36898871) |
| References: | Eur Urol. 2017 Mar;71(3):447-461. (PMID: 27324428) Cancer Treat Rev. 2020 Jan;82:101925. (PMID: 31785413) Trials. 2009 Jun 11;10:39. (PMID: 19519885) J Urol. 2017 Sep;198(3):552-559. (PMID: 28456635) Eur Urol. 2017 Jun;71(6):952-960. (PMID: 28081860) J Urol. 2000 Apr;163(4):1124-9. (PMID: 10737480) Ann Surg Oncol. 2018 Aug;25(8):2484-2491. (PMID: 29717423) Lancet Oncol. 2020 Dec;21(12):1574-1588. (PMID: 32971005) Cancer Immunol Immunother. 2018 Mar;67(3):403-412. (PMID: 29150702) Sci Rep. 2016 Jan 25;6:19740. (PMID: 26804478) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) J Clin Oncol. 2019 Jan 1;37(1):44-51. (PMID: 30433852) J Oncol. 2019 Mar 10;2019:6230409. (PMID: 30984262) Lancet Oncol. 2021 Jan;22(1):107-117. (PMID: 33253641) Lancet Oncol. 2021 Jul;22(7):919-930. (PMID: 34051177) Stat Med. 2003 Jul 30;22(14):2239-56. (PMID: 12854091) JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714) Bladder Cancer. 2016 Apr 27;2(2):215-224. (PMID: 27376140) Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1168-1171. (PMID: 30012528) Eur Urol. 2016 Jun;69(6):1046-52. (PMID: 26803476) JAMA Oncol. 2017 Sep 14;3(9):e172411. (PMID: 28817753) Clin Cancer Res. 2021 Aug 15;27(16):4599-4609. (PMID: 34117034) Bladder Cancer. 2015 Mar 30;1(1):29-30. (PMID: 26807434) Expert Opin Biol Ther. 2019 Sep;19(9):927-935. (PMID: 31272242) Immunotargets Ther. 2020 Feb 13;9:1-11. (PMID: 32104666) Cancer. 2007 Apr 15;109(8):1499-505. (PMID: 17340590) N Engl J Med. 2012 Apr 19;366(16):1477-88. (PMID: 22512481) Bladder Cancer. 2016 Apr 27;2(2):165-202. (PMID: 27376138) |
| معلومات مُعتمدة: | K08 CA248967 United States CA NCI NIH HHS; P30 CA006973 United States CA NCI NIH HHS; P30 CA086862 United States CA NCI NIH HHS; R01 CA235681 United States CA NCI NIH HHS; UM1 CA186691 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Bacillus Calmette-Guerin; Bacillus Calmette-Guerin unresponsive; Bladder cancer; Clinical trial; Durvalumab; Non–muscle invasive; PD-L1; Radiation; Urothelial carcinoma |
| المشرفين على المادة: | 0 (BCG Vaccine) 28X28X9OKV (durvalumab) 0 (Adjuvants, Immunologic) |
| تواريخ الأحداث: | Date Created: 20230130 Date Completed: 20230515 Latest Revision: 20240603 |
| رمز التحديث: | 20240603 |
| مُعرف محوري في PubMed: | PMC10192088 |
| DOI: | 10.1016/j.eururo.2023.01.017 |
| PMID: | 36717286 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-7560 |
|---|---|
| DOI: | 10.1016/j.eururo.2023.01.017 |